SuperworthShuttle Pharmaceuticals SHPH
- Market cap
- $23.2M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Shuttle Pharmaceuticals' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $1M+56% | $710.4K+62% | $586.1K−36% | $645.7K−23% | $1.4M+34% | $986.4K+39% | $1.6M+169% | $1M+59% | $943.5K−33% | $511.9K−48% | $267.2K−83% | $55.7K−95% |
| SG&A | $265.6K+224% | $316.7K+236% | $324.6K+27% | $310K+48% | $329K+24% | $429.1K+36% | $596.9K+84% | $2.3M+657% | $886.1K+169% | $1.8M+330% | $1.2M+94% | $2M−15% |
| −$1.6M+95% | −$1.3M+73% | −$1.4M−10% | −$1.5M+1% | −$3.1M+91% | −$1.8M+39% | −$3M+113% | −$3.9M+164% | −$2.3M−26% | −$2.8M+57% | −$2.2M−25% | −$3.9M+1% | |
| Interest expense | $623.5K+1% | $532K+5157% | $497.5K−18% | $430.7K−41% | $272.7K−56% | $6.6K−99% | $11.9K−98% | $21.7K−95% | $18.9K−93% | $18.3K+178% | $12.1K+2% | $0 |
| Pre-tax income | −$1.8M+78% | −$1.6M+119% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$1.8M+80% | −$1.6M+100% | −$1.7M+78% | −$2M−7% | −$3.8M+111% | −$1.6M−3% | −$3.1M+76% | −$3.7M+83% | −$2.3M−38% | −$2.6M+64% | −$2.2M−30% | −$3.1M−15% |
| −$227.50+14% | −$205.00+71% | −$207.50+46% | −$241.20−22% | −$398.30+75% | −$81.40−60% | −$76.00−63% | −$32.91−86% | −$10.50−97% | −$9.50−88% | −$4.30−94% | −$3.10−91% | |
| 7.9K+55% | 8K+31% | 8.3K+22% | 8.4K+18% | 9.5K+21% | 19.6K+145% | 40.2K+384% | 112.6K+1238% | 223.4K+2251% | 275.8K+1305% | 503.2K+1152% | 1M+802% |
Interest expense: Q1 FY22: 6 months less the 3 months printed beside them.
Net income: Q4 FY22 and Q4 FY23: not printed by the filing, worked out from its own lines.
EPS, diluted: 5 periods, Q1 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY22: share-days: the 6-month average less the second quarter's. Q3 FY22: not printed by the filing, worked out from its own lines. 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Shuttle Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SHPHShuttle Pharmaceuticals | $23.2M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $69M | 11.1× | 14.5× | 0.4× | −3% | 3.7% |
More on Shuttle Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .